Back to Search Start Over

Revisiting the NIH Taskforce on the Research needs of Eosinophil-Associated Diseases (RE-TREAD)

Authors :
Amy D. Klion
Praveen Akuthota
Steven J. Ackerman
Paneez Khoury
Marc E. Rothenberg
Sameer K. Mathur
Patricia C. Fulkerson
Kristin M. Leiferman
Lisa A. Spencer
Dagmar Simon
Michael Minnicozzi
Florence Roufosse
Joseph R. Arron
Jean-Emmanuel Kahn
Margaret H. Collins
Levi Schaffer Francesca
Hans-Uwe Simon
Gerald J. Gleich
Jonathan Steinfeld
Elizabeth A. Jacobsen
Calman Prussin
Rashmi Gopal-Srivastava
Andrew J. Wardlaw
Peter F. Weller
Kathleen Sable
Michael E. Wechsler
Bruce S. Bochner
Publication Year :
2018
Publisher :
Society for Leukocyte Biology, 2018.

Abstract

Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patient-reported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated Diseases (TREAD). RE-TREAD focused on gaps in basic science, translational, and clinical research on eosinophils and eosinophil-related pathogenesis. Improved recapitulation of human eosinophil biology and pathogenesis in murine models was felt to be of importance. Characterization of eosinophil phenotypes, the role of eosinophil subsets in tissues, identification of biomarkers of eosinophil activation and tissue load, and a better understanding of the role of eosinophils in human disease were prioritized. Finally, an unmet need for tools for use in clinical trials was emphasized. Histopathologic scoring, patient- and clinician-reported outcomes, and appropriate coding were deemed of paramount importance for research collaborations, drug development, and approval by regulatory agencies. Further exploration of the eosinophil genome, epigenome, and proteome was also encouraged. Although progress has been made since 2012, unmet needs in eosinophil research remain a priority. Review on eosinophil biology and eosinophil-related disorders (2012–2017) with a focus on continued unmet needs in eosinophil-associated diseases.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....fce7ac3a68d55710bd9156f44fe07f1e
Full Text :
https://doi.org/10.7892/boris.116903